Fig. 3: In vivo protection of CAV-F34 and CAV-F6 against avian influenza viruses. | Nature Communications

Fig. 3: In vivo protection of CAV-F34 and CAV-F6 against avian influenza viruses.

From: Broad neuraminidase antibodies confer protection against seasonal and avian influenza viruses

Fig. 3

A, B Experimental design for pre-exposure prophylaxis (A) and post-exposure therapy (B). BALB/c mice (6-8 weeks old, female) were intraperitoneally administered 10 mg/kg (H7N9) or 20 mg/kg (H5N1) mAbs either 24 h before challenge (prophylaxis) or 24 h post-challenge (therapy). Survival was monitored for 14 days. C, D Protection against A/Anhui/1/2013 (H7N9) NIBGR-268: Prophylaxis (C) and therapy (D) with CAV-F34 (green) and CAV-F6 (blue). Yellow: PBS control. Left panels: mean percentage change in body weight relative to baseline. Right panels: survival curves. Five animals were used per group (n = 5), and error bars represent SD. E, F Protection against A/dairy cattle/Texas/24-008749-003-original/2024 (H5N1): Prophylaxis (E) and therapy (F). For (E–F) Data presentation identical to (C–D).

Back to article page